Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study

References

• National Multiple Sclerosis Society. What is MS? [Internet] 2018 Mar 23 [cited 2019 Nov 8]. Available from: https://www.nationalmssociety.org/What-is-MS/What-Causes-MS
   Google Scholar
• Hunter SF. Overview and diagnosis of multiple sclerosis. Am J Manag Care. 2016;22(6 Suppl):S141–S50. Jun
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis International Foundation. Atlas of MS [Internet]. 2013 [cited 2019 Nov 8]. Available from: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
   Google Scholar
• Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med. 2011;78(2):161–175.
   PubMedGoogle Scholar
• Kim W, Zandona ME, Kim SH, et al. Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol. 2015;11(1):9–19. Jan
   PubMed Web of Science ®Google Scholar
• Gilenya (fingolimod) capsules: highlights of prescribing information [Internet]. 2016 [cited 2019 Nov 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022527s018lbl.pdf
   Google Scholar
• Aubagio (teriflunomide) tablets: highlights of prescribing information [Internet]. 2016 [cited 2019 Nov 8]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202992s002lbl.pdf
   Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–556.
   PubMed Web of Science ®Google Scholar
• Kappos L, O’Connor P, Radue E-W, et al. Long-term effects of fingolimod in multiple sclerosis the randomized FREEDOMS extension trial. Neurology. 2015;84(15):1582–1591.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–1303.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–256.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20(6):705–716.
   PubMed Web of Science ®Google Scholar
• Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing–remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;18(9):CD011381.
   Google Scholar
• Nixon R, Bergvall N, Tomic D, et al. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing–remitting multiple sclerosis. Adv Ther. 2014;31(11):1134–1154.
   PubMed Web of Science ®Google Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618–625.
   PubMedGoogle Scholar
• Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;151(3):203–205.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Danni M, Taffi R, et al. Persistence to oral disease-modifying therapies in multiple sclerosis patients. J Neurol. 2017;264(11):2325–2329.
   PubMed Web of Science ®Google Scholar
• Boster A, Nicholas J, Wu N, et al. Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database. Neurol Ther. 2017;6(1):91–102.
   PubMed Web of Science ®Google Scholar
• Vu N, Bradshaw M, Moses H, et al. Efficacy and tolerability of fingolimod, dimethyl fumarate, and teriflunomide in patients with multiple sclerosis: real world experience from a single center. Neurology. 2016;86(16 Suppl):168.
   Google Scholar
• Johnson KM, Zhou H, Lin F, et al. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. JMCP. 2017;23(8):844–852.
   PubMedGoogle Scholar
• Kozma CM, Munschauer FE, Phillips AL. Relapse rates of patients with multiple sclerosis newly initiating subcutaneous interferon b-1a vs oral disease-modifying drugs in the real world. Poster session presented at: Disease modification. 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); 2016 Jun 1–4; National Harbor, MD.
   Google Scholar
• Hansen L. The Truven Health MarketScan Databases for life sciences researchers [Internet]. 2017 [cited 2019 Nov 8]. Available from: https://truvenhealth.com/Portals/0/Assets/2017-MarketScan-Databases-Life-Sciences-Researchers-WP.pdf
   Google Scholar
• Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. JMCP. 2002;8(6):469–476.
   PubMedGoogle Scholar
• Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13(1):138.
   PubMedGoogle Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidem Drug Saf. 2006;15(8):565–574.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(4):458–468.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(10):977–986.
   PubMed Web of Science ®Google Scholar
• Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing–remitting multiple sclerosis. Mult Scler. 2016;22(10):1297–1305.
   PubMed Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin. 2013;29(12):1647–1656.
   PubMed Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One. 2014;9(2):e88472.
   PubMed Web of Science ®Google Scholar